Author(s)

J. Staals, S. D. Makin, F. N. Doubal, M. S. Dennis, J. M. Wardlaw

ISBN

1526-632X (Electronic) 0028-3878 (Linking)

Publication year

2014

Periodical

Neurology

Periodical Number

14

Volume

83

Pages

1228-34

Author Address

From the Centre for Clinical Brain Sciences (S.D.J.M., F.N.D., M.S.D., J.M.W.), University of Edinburgh, UK; and Department of Neurology and Cardiovascular Research Institute Maastricht (J.S.), Maastricht University Medical Centre, the Netherlands. From the Centre for Clinical Brain Sciences (S.D.J.M., F.N.D., M.S.D., J.M.W.), University of Edinburgh, UK; and Department of Neurology and Cardiovascular Research Institute Maastricht (J.S.), Maastricht University Medical Centre, the Netherlands. joanna.wardlaw@ed.ac.uk.

Full version

OBJECTIVES: In this cross-sectional study, we tested the construct validity of a “total SVD score,” which combines individual MRI features of small-vessel disease (SVD) in one measure, by testing associations with vascular risk factors and stroke subtype. METHODS: We analyzed data from patients with lacunar or nondisabling cortical stroke from 2 prospective stroke studies. Brain MRI was rated for the presence of lacunes, white matter hyperintensities, cerebral microbleeds, and perivascular spaces independently. The presence of each SVD feature was summed in an ordinal “SVD score” (range 0-4). We tested associations with vascular risk factors, stroke subtype, and cerebral atrophy using ordinal regression analysis. RESULTS: In 461 patients, multivariable analysis found that age (odds ratio [OR] 1.10, 95% confidence interval [CI] 1.08-1.12), male sex (OR 1.58, 95% CI 1.10-2.29), hypertension (OR 1.50, 95% CI 1.02-2.20), smoking (OR 2.81, 95% CI 1.59-3.63), and lacunar stroke subtype (OR 2.45, 95% CI 1.70-3.54) were significantly and independently associated with the total SVD score. The score was not associated with cerebral atrophy. CONCLUSIONS: The total SVD score may provide a more complete estimate of the full impact of SVD on the brain, in a simple and pragmatic way. It could have potential for patient or risk stratification or early efficacy assessment in clinical trials of interventions to prevent SVD progression and may (after further testing) have a useful role in clinical practice.